C-C. Lin

724 citations

47 papers · 646 · h-index 11

Impact in

Biotechnology top 5%
- Cancer Research and Treatments
Hepatology top 10%
- Hepatocellular Carcinoma Treatment and Prognosis

Papers in

Pulmonary and Respiratory Medicine 17
- Lung Cancer Treatments and Mutations 9
- Prostate Cancer Treatment and Research 4
Hepatology 6
- Hepatocellular Carcinoma Treatment and Prognosis 6

Co-authors: Lin Tm (1 shared paper)Jin‐Shing Chen (2 shared papers)Chien‐Jen Chen (1 shared paper)Yang Chul-Su (1 shared paper)JH Wang (1 shared paper)I.-Shyan Sheen (1 shared paper)L-T. Chen (1 shared paper)Yee Chao (1 shared paper)
Journals: Annals of Oncology (27 papers)British Journal of Cancer (3 papers)British Journal of Radiology (1 paper)Clinical Pharmacology & Therapeutics (1 paper)Journal for ImmunoTherapy of Cancer (1 paper)
Partner nations: Taiwan United States South Korea

In The Last Decade

C-C. Lin

44 papers receiving 627 citations

Peers

Countries citing papers authored by C-C. Lin

Since Specialization

Citations

This map shows the geographic impact of C-C. Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C-C. Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C-C. Lin more than expected).

Fields of papers citing papers by C-C. Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C-C. Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C-C. Lin. The network helps show where C-C. Lin may publish in the future.

Co-authors

The 25 scholars most cited alongside C-C. Lin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with C-C. Lin Line = papers co-authored together C-C. Lin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 47 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Hepatitis B virus markers in Chinese twins. PubMed ·Lin Tm, Chien‐Jen Chen, Wu Mm, Yang Chul-Su, Jin‐Shing Chen, C-C. Lin, Kwang Ty, Hsu St	1989	151
2	A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients British Journal of Cancer ·TS Yang, SN Lu, Yee Chao, I.-Shyan Sheen, C-C. Lin, T. Wang, JH Wang, L-Y Liao	2010	145
3	A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies British Journal of Cancer ·C-C. Lin, Wu‐Chou Su, C-J. Yen, Chih‐Hung Hsu, W-P Su, Yen‐Shen Lu, Holger Fritsch, Tillmann Taube	2014	69
4	Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection British Journal of Cancer ·C-C. Lin, Yee‐Chun Chen, S-M Lin, Y‐F Liaw +2 others	2012	31
5	1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC) Annals of Oncology ·Mimi I-Nan Hu, Vivek Subbiah, Lori J. Wirth, M Schuler, Aaron Scott Mansfield, Marcia S. Brose, Giuseppe Curigliano, Sophie Leboulleux	2020	31
6	Interconnections between autophagy and the coagulation cascade in hepatocellular carcinoma Cell Death and Disease ·K-D Chen, M-C Tsai, C-H Wu, H-J Yang, L-Y Chen, Toshiaki Nakano, Shigeru Goto, K-T Huang	2014	30
7	(Nucleic Acids Res., 34:W571-W577)CRSD: a comprehensive web server for composite regulatory signature discovery NCHU Institutional Repository CRIS ·Liu Cc, C-C. Lin, Chen Wse, Chen Hy, Chang Pc, Chen Jjw, Yang Pc	2006	18
8	Risk of tumour progression in early-stage hepatocellular carcinoma after radiofrequency ablation British journal of surgery ·C-C. Lin, C-J Lin, W-T Chen, S-M Lin +1 other	2009	18
9	Factor VII promotes hepatocellular carcinoma progression through ERK-TSC signaling Cell Death Discovery ·M-C Tsai, K-D Chen, K-T Huang, C-H Wu, I.-Ying Kuo, L-Y Chen, T-H Hu, Shigeru Goto	2015	18
10	The potential impact of sleep-related movement disorders on stroke risk: a population-based longitudinal study QJM ·J-H Yin, C-C. Lin, Y-F Sung, C-H Chung, W-C Chien, G-Y Lin, J.-T. Lee +5 others	2017	15
11	1256MO Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours Annals of Oncology ·Benjamin Besse, Alexander Drilon, BC Cho, D. Ross Camidge, Joel W. Neal, C-C. Lin, S.V. Liu, M. Nagasaka	2024	12
12	Impaired natural killer cytotoxicity during recrudescence of recurrent herpes simplex virus type 1 infection. PubMed ·Y C Kuo, C Y Lin, Cheng Sf, C-C. Lin, Liu Wt	1987	9
13	Radiofrequency ablation for hepatocellular carcinoma: use of lowvsmaximal radiofrequency power British Journal of Radiology ·Therese Capalongan Macatula, C-C. Lin, C-J Lin, W-T Chen, S-M Lin	2012	9
14	1765O Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC) Annals of Oncology ·William Kevin Kelly, Daniel Costin Danila, C-C. Lin, Jia-Lin Lee, Nobuaki Matsubara, Patrick J. Ward, Andrew J. Armstrong, David William Pook	2023	9
15	(Nucleic Acids Res., 34:4069-4080)Topology-based cancer classification and related pathway mining using microarray data NCHU Institutional Repository CRIS ·Liu Cc, Chen Wse, C-C. Lin, Liu Hc, Chen Hy, Yang Pc, Chang Pc, Chen Jjw	2006	7
16	561P Phase Ib study of ribociclib (R) + trametinib (T) in patients (pts) with metastatic/advanced solid tumours Annals of Oncology ·Patricia Mucci LoRusso, Marwan Fakih, Filip De Vos, Joseph Thaddeus Beck, Jaime Rafael Merchan, Geoffrey Ira Shapiro, C-C. Lin, Jayesh Desai	2020	6
17	662MO Phase I, multi-center, dose-escalation and dose-expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors Annals of Oncology ·C-C. Lin, Jaspreet Singh Grewal, Joaquina Celebre Baranda, Jian Zhang, L-Y. Bai, Y-M. Yeh, David Sommerhalder, Guang Li	2023	6
18	1918P Final analysis of RIFTOS MKI, a global, non-interventional study assessing the use of multikinase inhibitors (MKIs) for the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC) Annals of Oncology ·Marcia S. Brose, Johannes W. A. Smit, C-C. Lin, Masayuki Tori, Daniel W. Bowles, Frank P. Worden, DER-CHUNG SHEN, S-M. Huang	2020	5
19	Phase I/II study of S 49076, a MET/AXL/FGFR inhibitor, in combination with gefitinib in EGFR-mutated NSCLC patients who progress on EGFR tyrosine kinase inhibitor Annals of Oncology ·K. Park, Fortunato Ciardiello, Toyoaki Hida, Darren Wan-Teck Lim, C-C. Lin, Haruyasu Murakami, Makoto Nishio, Frederique Cantero	2017	4
20	1287P Efficacy and safety of entrectinib in locally advanced/metastatic ROS1 fusion-positive NSCLC: An updated integrated analysis Annals of Oncology ·Matthew Krebs, Filippo de Braud, Salvatore Siena, Alexander Drilon, Robert Charles Doebele, Manish Ramesh Patel, Byoung Chul Cho, Stephen V. Liu	2020	4

About C-C. Lin

C-C. Lin is a scholar working on Pulmonary and Respiratory Medicine, Hepatology, Oncology, Endocrinology, Diabetes and Metabolism and Immunology, having authored 47 papers that have together received 646 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (9 papers), Cancer Immunotherapy and Biomarkers (6 papers), Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Thyroid Cancer Diagnosis and Treatment (5 papers), Prostate Cancer Treatment and Research (4 papers), Immunotherapy and Immune Responses (3 papers), Hepatitis B Virus Studies (2 papers) and Drug Solubulity and Delivery Systems (1 paper). The work is most often cited by research in Biotechnology (77 citations), Hepatology (82 citations), Biochemistry (53 citations), Epidemiology (175 citations) and Cancer Research (43 citations). C-C. Lin has collaborated with scholars based in Taiwan, United States and South Korea. Frequent co-authors include Lin Tm, Jin‐Shing Chen, Chien‐Jen Chen, Yang Chul-Su, JH Wang, I.-Shyan Sheen, L-T. Chen, Yee Chao, Yee‐Chun Chen and Holger Fritsch. Their work appears in journals such as Annals of Oncology, British Journal of Cancer, British Journal of Radiology, Clinical Pharmacology & Therapeutics and Journal for ImmunoTherapy of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

C-C. Lin

Impact in

Papers in i

In The Last Decade

C-C. Lin

Peers

Countries citing papers authored by C-C. Lin

Fields of papers citing papers by C-C. Lin

All Works

About C-C. Lin

Explore authors with similar magnitude of impact

Papers in